All In Biotech

Drug Trial Radar · NCT00557440

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

A Multi-center, Randomized, Double-blind, Double Dummy, Placebo and Active Controlled Crossover Study, to Investigate the 24 Hour FEV1 Profile of a Single Dose of QMF TWISTHALER Device in Adult Patients With Persistent Asthma

Last checked: Nov 19, 2026Latest source record: Mar 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

37

Actual

Start

Nov 2007

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Nov 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to provide data about the 24 hours FEV1 profile, safety and tolerability of indacaterol/mometasone TWISTHALER device compared to placebo and using fluticasone/salmeterol as an active control.

Conditions

  • Asthma

Interventions

  • fluticasone propionate/salmeterolDrug

    Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.

  • indacaterol maleate / mometasone furoateDrug

    Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.

  • placebo to indacaterol/mometasoneDrug

    Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.

  • placebo to fluticasone propionate/salmeterolDrug

    Placebo to fluticasone propionate / salmeterol delivered via MDDPI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)Time frame: Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigator Site

    Aalst, Belgium

  • Novartis Investigator site

    Ghent, Belgium

  • Novartis Investigator Site

    Berlin, Germany

  • Novartis Investigator Site

    Hanover, Germany

  • Novartis Investigator Site

    Landsberg, Germany

  • Novartis Investigator Site

    Rostock, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.